Literature DB >> 17300799

Human amniotic fluid-derived stem cells are rejected after transplantation in the myocardium of normal, ischemic, immuno-suppressed or immuno-deficient rat.

Angela Chiavegato1, Sveva Bollini, Michela Pozzobon, Andrea Callegari, Lisa Gasparotto, Jenny Taiani, Martina Piccoli, Elisabetta Lenzini, Gino Gerosa, Igor Vendramin, Emanuele Cozzi, Annalisa Angelini, Laura Iop, Giovanni F Zanon, Anthony Atala, Paolo De Coppi, Saverio Sartore.   

Abstract

Human amniotic fluid-derived stem (AFS) cells, similarly to embryonic stem cells, could possess privileged immunological characteristics suitable for a successful transplantation even in a discordant xenograft system. We investigated whether AFS cells could be fruitfully used in a rat model of myocardial infarction. c-kit immunomagnetic-sorted AFS cells were characterized by flow cytometric analysis and cytospins as well as reverse-transcription polymerase chain reaction, Western blotting and immunocytochemistry for cardiovascular differentiation markers. In vitro, AFS cell phenotypic conversion was assayed by cardiovascular-specific induction media or co-cultured with rat neonatal cardiomyocytes. AFS cells showed mRNAs and/or protein for endothelial (angiopoietin, CD146) and smooth muscle (smoothelin) cells, and cardiomyocyte (Nkx2.5, MLC-2v, GATA-4, beta-MyHC) markers. Acquisition of a cardiomyocyte-like phenotype in rare AFS cells could be seen only in co-cultures with rat neonatal cells. In vivo, AFS cells xenotransplantated in a rat model of myocardial infarction, with or without cyclosporine treatment, or in intact heart from immuno-competent or immuno-deficient animals were acutely rejected due to the different recruitment of recipient CD4(+), CD8(+) T and B lymphocytes, NK cells and macrophages. This reaction is most likely to be linked to expression of B7 co-stimulatory molecules CD80 and CD86 as well as macrophage marker CD68 on AFS cells. Xenotransplanted AFS cells gave also rise in some animals to cell masses in the subendocardium and myocardium suggestive of a process of chondro-osteogenic differentiation. Despite AFS cells in vitro can differentiate to some extent to cells of cardiovascular lineages, their in vivo use in xenotransplantation for cell therapy of myocardial infarction is hampered by their peculiar immunogenic properties and phenotypic instability.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17300799     DOI: 10.1016/j.yjmcc.2006.12.008

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  51 in total

1.  Human amniotic fluid-derived stem cells can differentiate into hepatocyte-like cells in vitro and in vivo.

Authors:  Hui Liu; Da-qing Liu; Bao-wei Li; Li-dong Guan; Zhi-feng Yan; Ya-li Li; Xue-tao Pei; Wen Yue; Min Wang; Yan-ping Lu; Hong-mei Peng; Yang Lv
Journal:  In Vitro Cell Dev Biol Anim       Date:  2011-09-22       Impact factor: 2.416

Review 2.  Biological characteristics of stem cells from foetal, cord blood and extraembryonic tissues.

Authors:  Hassan Abdulrazzak; Dafni Moschidou; Gemma Jones; Pascale V Guillot
Journal:  J R Soc Interface       Date:  2010-08-25       Impact factor: 4.118

Review 3.  Wharton's jelly mesenchymal stem cells as candidates for beta cells regeneration: extending the differentiative and immunomodulatory benefits of adult mesenchymal stem cells for the treatment of type 1 diabetes.

Authors:  Rita Anzalone; Melania Lo Iacono; Tiziana Loria; Antonino Di Stefano; Pantaleo Giannuzzi; Felicia Farina; Giampiero La Rocca
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

4.  In vitro and in vivo cardiomyogenic differentiation of amniotic fluid stem cells.

Authors:  Sveva Bollini; Michela Pozzobon; Muriel Nobles; Johannes Riegler; Xuebin Dong; Martina Piccoli; Angela Chiavegato; Anthony N Price; Marco Ghionzoli; King K Cheung; Anna Cabrelle; Paul R O'Mahoney; Emanuele Cozzi; Saverio Sartore; Andrew Tinker; Mark F Lythgoe; Paolo De Coppi
Journal:  Stem Cell Rev Rep       Date:  2011-06       Impact factor: 5.739

5.  Role of hepatocyte growth factor in the immunomodulation potential of amniotic fluid stem cells.

Authors:  Tullia Maraldi; Francesca Beretti; Marianna Guida; Manuela Zavatti; Anto De Pol
Journal:  Stem Cells Transl Med       Date:  2015-04-14       Impact factor: 6.940

6.  Blood-derived small Dot cells reduce scar in wound healing.

Authors:  Wuyi Kong; Shaowei Li; Michael T Longaker; H Peter Lorenz
Journal:  Exp Cell Res       Date:  2008-02-09       Impact factor: 3.905

Review 7.  Application of stem cells in bone repair.

Authors:  Elaine Y L Waese; Rita A Kandel; Rita R Kandel; William L Stanford
Journal:  Skeletal Radiol       Date:  2008-01-12       Impact factor: 2.199

8.  Cardiac cell therapy in vitro: reproducible assays for comparing the efficacy of different donor cells.

Authors:  Rebecca Klinger; Nenad Bursac
Journal:  IEEE Eng Med Biol Mag       Date:  2008 Jan-Feb

Review 9.  CD117(+) amniotic fluid stem cells: state of the art and future perspectives.

Authors:  Mara Cananzi; Paolo De Coppi
Journal:  Organogenesis       Date:  2012-07-01       Impact factor: 2.500

Review 10.  Characterizing functional stem cell-cardiomyocyte interactions.

Authors:  Nenad Bursac; Robert D Kirkton; Luke C McSpadden; Brian Liau
Journal:  Regen Med       Date:  2010-01       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.